COMP <GO>
NBIX vs UNH // FORWARD P/E MULTIPLE
Neurocrine Biosciences Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: NBIX 8
— UNH 6
▲ FORWARD P/E MULTIPLE LEADER: UNH
LAST: $146.10 (-0.19%) • MKT CAP: $14.85B
forward-pe
26.1x
LAST: $406.97 (-0.96%) • MKT CAP: $365.29B
forward-pe
17.7x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NBIX VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NBIX | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 88.57% | +7.43 | NBIX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 15.70% | 11.47% | +4.23 | NBIX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 22.8x | 16.5x | +6.32 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 5.03% | 6.47% | -1.44 | UNH | /fcf-yield <GO> |
| Operating Margin | 21.60% | 4.82% | +16.78 | NBIX | /operating-margins <GO> |
| Net Profit Margin | 16.70% | 3.14% | +13.56 | NBIX | /net-margins <GO> |
| Revenue Growth (YoY) | 21.40% | 6.46% | +14.94 | NBIX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.32% | -2.32 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.13 | 3.12 | +5.01 | NBIX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | NBIX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.11% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.2 | 57.4 | -2.20 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.13 | 0.33 | +0.80 | NBIX | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 26.1x | 17.7x | +8.36 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $14.85B | $365.29B | -$350.44B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NBIX REV | UNH REV | NBIX GROSS % | UNH GROSS % | NBIX FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.86B | $447.57B | 98.2% | 88.7% | $748.7M | $16.07B |
| FY 2024 | $2.36B | $400.28B | 98.6% | 88.3% | $557.2M | $20.70B |
| FY 2023 | $1.89B | $371.62B | — | 89.6% | $305.0M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NBIX // BETA 1.13
UNH // BETA 0.33